The WBB Securities report, dated April 11, 2008, assigned a Strong Buyrating to the Company, and reiterated a 12-month target price of $13.00.The report's introduction stated, "In the past eight days, threesignificant events have taken place that validate CBLI's science,underscore the company's viability and improve the company's outlook." Thereport then summarized these events.

Interested parties should contact WBB Securities for more information aboutthe report. For more information on WBB Securities, please visit:www.wbbsec.com.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development companyleveraging its proprietary discoveries about programmed cell death to treatcancer and protect normal tissues from exposure to radiation and otherstresses. The Company has strategic partnerships with the ClevelandClinic, Roswell Park Cancer Institute, ChemBridge Corporation and the ArmedForces Radiobiology Research Institute. To learn more about ClevelandBioLabs, Inc., please visit the company's website athttp://www.cbiolabs.com.

This press release does not suggest or imply an endorsement by the Companyof any projection or recommendation included in any analyst report.

This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements reflect management's current expectations, as of the date ofthis press release, and involve certain risks and uncertainties. TheCompany's actual results could differ materially from those anticipated inthese forward-looking statements as a result of various factors. Some ofthe factors that could cause future results to materially differ from therecent results or those projected in forward-looking statements include the"Risk Factors" described in the Company's periodic filings with theSecurities and Exchange Commission.